Cancer Vaccine for NSCLC and Melanoma Could Be Paradigm-Changing
Source: CureToday, August 2024
The cancer vaccine, mRNA-4157, garnered immune responses of 30 weeks among some patients with melanoma and lung cancer, study results showed.
Some patients with skin and lung cancer continued to experience immune responses for 30 weeks after treatment with the cancer vaccine mRNA-4157, according to new study results.
Findings from the phase 1 KEYNOTE-603 study, published in Cancer Discovery, showed that among patients treated with mRNA-4157 and the immune checkpoint inhibitor Keytruda (pembrolizumab) — four with resected (surgically removed) non-small cell lung cancer and 12 with resected cutaneous melanoma — provide insight into the ability of neoantigen therapies such as mRNA-4157 to produce anti-tumor responses, as one researcher told CURE®.